Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.19 -0.42 (-26.09%)
At close: Sep 30, 2026 · 4:00 PM EDT

Chemomab Therapeutics (CMMB) Other Non-Current Liabilities (2018 - 2019)

Updated

Chemomab Therapeutics (CMMB) recorded Other Non-Current Liabilities of $9.17 million in Q3 2019.

Analysis

Chemomab Therapeutics (CMMB) Other Non-Current Liabilities (2018 - 2019) Analysis & Trends

At the end of FY2018, Chemomab Therapeutics reported Other Non-Current Liabilities of $6.98 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Chemomab Therapeutics 8.56 Mn 8.56 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 9.17 Mn
Dec 31, 2018 6.98 Mn
API Access

Chemomab Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=CMMB&period=max&api_key=YOUR_API_KEY